학술논문
Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment.
Document Type
Letter
Author
Source
Subject
*ANTIBODY formation
*COVID-19 vaccines
*DIFFUSE large B-cell lymphomas
*
*
Language
ISSN
1042-8194
Abstract
The deleterious effect of anti-CD20 therapy on the humoral response to SARS-CoV-2 vaccination is evident both in patients with autoimmune and lymphoproliferative diseases, although the response rates are heterogeneous [[8], [10]]. A recent meta-analysis showed that patients on active anti-CD20 therapy (3 months since last dose) had poor responses to all types of vaccines including influenza virus vaccination, with seroconversion rates from 0% to 25% [[4]]. Keywords: COVID-19; mRNA vaccine; Lymphoma; anti-CD20 immunotherapy; CD19+ B lymphocytes EN COVID-19 mRNA vaccine Lymphoma anti-CD20 immunotherapy CD19+ B lymphocytes 1474 1478 5 06/03/22 20220601 NES 220601 Hematologic and immunocompromised patients have a higher risk for complications after SARS-Cov-2 infection with a high mortality rate compared to the healthy population [[1]]. [Extracted from the article]